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Implications of C1q/TNF-related
protein superfamily in patients with
coronary artery disease
Yanwei Zhang1,3,4, Caihong Liu1,4, Jing Liu1, Rui Guo1, Zheyi Yan1,3, Wenxia Liu1,
Wayne Bond Lau2, Xiangying Jiao1, Jimin Cao1, Kun Xu3, Yongping Jia3, Xinliang Ma2 &
Yajing Wang2*
The C1q complement/TNF-related protein superfamily (CTRPs) displays differential effects on the
regulation of metabolic homeostasis, governing cardiovascular function. However, whether and how
they may serve as predictor/pro-diagnosis factors for assessing the risks of coronary artery disease
(CAD) remains controversial. Therefore, we performed a clinical study to elaborate on the implication
of CTRPs (CTRP1, CTRP5, CTRP7, and CTRP15) in CAD. CTRP1 were significantly increased, whereas
CTRP7 and CTRP15 levels were decreased in CAD patients compared to the non-CAD group. Significant
differences in CTRP1 levels were discovered between the single- and triple-vascular-vessel lesion
groups. ROC analysis revealed that CTRP7 and CTRP15 may serve as CAD markers, while CTRP1 may
serve as a marker for the single-vessel lesion of CAD. CTRP1 and CTRP5 can serve as markers for the
triple-vessel lesion. CTRP1 may serve as an independent risk predictor for triple-vessel lesion, whereas
CTRP15 alteration may serve for a single-vessel lesion of CAD. CTRP1 may serve as a novel superior
biomarker for diagnosis of severity of vessel-lesion of CAD patients. CTRP7, CTRP15 may serve as more
suitable biomarker for the diagnosis of CAD patients, whereas CTRP5 may serve as an independent
predictor for CAD. These findings suggest CTRPs may be the superior predictive factors for the vascular
lesion of CAD and represent novel therapeutic targets against CAD.
Coronary artery disease (CAD) is one of the major cardiovascular diseases, which has a serious impact on human
health1. CAD is a group of diseases including myocardial infarction, sudden angina pectoris, unstable angina
pectoris, myocardial infarction, and sudden coronary death2. Multiple risk factors for CAD have been identified,
which are highly associated with metabolism influencer/regulators including obesity, hypertension, dyslipidemia,
diabetes, smoking, gender, age, etc.3. However, the sensitivity of the indicators limits the prediction and prognosis
of CAD. Identification of new marker or indicator is in great need.
Previous studies suggest that adipokines, well-defined adipocyte endocrine factors, are important determinants for cardiovascular disorders with or without diabetes. Previous investigations implicate adiponectin
(APN)’s circulationary level is negatively associated with patients who suffered coronary artery disease and4.
CTRP (C1q complement/TNF-related protein) as a newly discovered family have shown diversity and wide distribution. Some of CTRP family members have similar metabolic effects with that of adiponectin, whereas others
exert opposite effect as that adiponectin. Although emerging evidence suggests that CTRPs may serve as indicators for metabolic disorders, whether and how CTRPs may display its own unique potential relationship in
predicting disease, especially cardiovascular disorders, is largely under-investigated.
CTRP family contains 15 family members (CTRP1 to CTRP15). Their functions display the differences
and are highly related to their distributions5. Of all CTRPs identified to date, CTRP1, CTRP3, CTRP5, CTRP9,
CTRP12, CTRP7, and CTRP13 have been reported to exhibit metabolic regulation and cardiovascular effects in
animal models6–8. CTRP7 circulating levels are reduced in diet-induced diabetic or obese5,9, and CTRP7 deletion
attenuates obesity-linked glucose intolerance, adipose tissue inflammation, and hepatic stress10. CTRP15 is a
newly discovered actin that binds skeletal muscle and lipids in response to changes in energy status and predicts changes in metabolic circuits11. However, few CTRP members have been investigated in human studies and
1

Department of Physiology, Shanxi Medical University, Shanxi, China. 2Department of Emergency Medicine, Thomas
Jefferson University, Philadelphia, PA, USA. 3Department of Cardiology, The First Affiliated Hospital of Shanxi
Medical University, Shanxi, China. 4These authors contribute equally: Yanwei Zhang and Caihong Liu. *email: yajing.
wang@jefferson.edu

Scientific Reports |

(2020) 10:878 | https://doi.org/10.1038/s41598-020-57877-z

1

www.nature.com/scientificreports

www.nature.com/scientificreports/
Non-CAD

CAD

Variable

Yong

Elder

Single-vessel-Lesion Double-vessel-Lesion Triple-vessel-Lesion

P

Sex (M/F)

5/35

17/13

29/11

34/6

28/12

<0.001

Age (year)

34.80 ± 9.73

54.90 ± 8.29

61.13 ± 9.06

63.63 ± 10.61

64.05 ± 8.74

<0.001

Occlusion (N/Y)

40/0

30/0

36/4

36/4

30/10

<0.001

Hypertension (N/Y)

40/0

30/0

24/16

25/15

19/21

<0.001

Diabetes (N/Y)

40/0

30/0

31/9

32/8

28/12

<0.001

Smoker (N/Y)

40/0

27/3

33/7

36/4

34/6

0.106

TCH (mmol/L)

4.49 ± 0.92

4.67 ± 1.15

4.00 ± 1.06

4.07 ± 1.20

4.23 ± 1.21

0.030

Triglyceride (mmol/L)

1.03 ± 0.58

1.66 ± 0.62

1.65 ± 1.12

1.70 ± 0.82

2.17 ± 2.08

<0.001

HDL-cholesterol (mmol/L)

1.43 ± 0.36

1.02 ± 0.15

0.98 ± 0.24

0.92 ± 0.18

1.11 ± 0.76

<0.001

LDL-cholesterol (mmol/L)

2.20 ± 0.62

2.87 ± 0.88

2.29 ± 0.84

2.37 ± 0.96

3.02 ± 2.50

0.009

ALT(U/L)

20.80 ± 23.68 24.10 ± 15.00 28.96 ± 16.11

35.50 ± 37.08

40.98 ± 61.58

<0.001

AST(U/L)

27.87 ± 33.10 21.77 ± 6.48

27.61 ± 13.88

33.58 ± 28.96

38.93 ± 51.47

0.025

EF(%)

63.34 ± 8.72

60.58 ± 8.91

60.03 ± 7.45

59.28 ± 9.11

0.197

62.27 ± 9.71

Table 1. Clinical characteristics of participants in CAD and non-CAD groups. **p < 0.01 Comparison with
non-CAD control subjects. a, p < 0.05 Comparison between single-vessel and triple-vessel.

Non-CAD
Variable

Yong

CAD
Elder

Single-vessel-Lesion

Double-vessel-Lesion

Triple-vessel-Lesion P

CTRP1 (ng/ml)

5.28 ± 3.52

6.69 ± 5.36

6.32 ± 6.22

8.25 ± 9.26

11.31 ± 9.99a**

0.019

CTRP5 (ng/ml)

8.95 ± 3.18

9.82 ± 4.23

14.69 ± 14.36

10.75 ± 4.71

10.26 ± 10.00

0.080

CTRP7 (ng/ml)

44.81 ± 41.02

20.83 ± 23.72**

29.70 ± 51.53**

34.83 ± 53.62**

38.21 ± 78.17**

CTRP15 (ng/ml)

50.21 ± 34.79

40.40 ± 42.08*

40.40 ± 38.18*

26.82 ± 31.85***

27.29 ± 29.48***

0.005
<0.001

Table 2. Circulating levels of CTRPs of participants in CAD and non-CAD groups. **p < 0.01 Comparison
with non-CAD control subjects. a, p < 0.05 Comparison between single-vessel and triple-vessel.
results are often controversial. For instance, one study reported that CTRP1 may slow the pathogenesis of early
atherosclerosis and prevent the development of pathological blood vessels12. However, another study demonstrated that CTRP1 level is associated with coronary artery disease13,14. CTRP5 level is related to drug-eluting
stent implantation after stent restenosis15,16. However, the pathogenic or diagnostic role of CTRP5 in coronary
diseases remain unclear in CAD patients.
Although above results suggest that CTRPs are associated with metabolism syndromes and play important
role in the regulating cellular metabolism,, unclear relationship between circulating CTRPs and coronary artery
disease in clinic patients, complexity of CTRP family, and unclear interrelationship between members of CTRP
family with different biological function, limited the CTRPs’s clinical application both in therapeutic strategy
exploration and as prognostic biomarkers. Therefore, we initiated a clinic investigation on plasma concentrations
of CTRP1, CTRP5, CTRP7, and CTRP15, aiming to identify high potential markers to guidance new therapeutic
strategy specifically in coronary artery disease, and to predict the severity of CAD. Additionally, the interrelationship of CTRP family in CAD will be assessed.

Results

Subjects characteristics. A total of 190 subjects were enrolled in this study. All the demographic data, base-

line clinical and biochemical characteristics of the study subjects were summarized in Tables 1 and 2. Statistical
analysis showed that CAD patients had markedly higher levels of vascular occlusion, hypertension, diabetes,
total cholesterol (TCH), Triglyceride (TG), high density lipoprotein (HDL)-cholesterol, low density lipoprotein
(LDL)-cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Interestingly, circulating CTRP1 was significantly high in CAD patients, while CTRP7 and CTRP15 were decreased compared to nonCAD participants (Table 2, p < 0.01). In addition, CTRP7and CTRP15 levels were reduced in elder non-CAD
when compared with young non-CAD controls (Table 2).
To reveal the relationship between CTRPs and vascular lesions and the severity of lesion stages, we evaluated CTRPs levels in different vessel-lesions. Along with increased vascular lesions, CTRP1 and CTRP7 levels
increased with the numbers of vessel-lesions in CAD patients (P < 0.05). CTRP5 showed increase tendency in
age-matched groups. Notably, CTRP15 levels were decreased in CAD patients, and CTRP15 levels were lower in
multiple vessel-lesion group than that in the single-vessel-lesion group. Furthermore, we constructed two models
for multivariate regression analysis to assess the independent determinants for severity of diseased coronary vessels. In model 1, we included all risk factors and compared multiple vessel lesions (combining double-vessel and
triple-vessel lesion together) to single-vessel lesion. In model 2, we additionally adjusted the analysis by grouping
single-vessel and double-vessel as primary lesion and compared with triple-vessel lesion. Both models support
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Variable

OR

OR CI95%

P

CTRP1(ng/ml)

1.049*

1.002–1.097

0.039

Sex(M/F)

1.289

0.461–3.599

0.628

Age(year)

0.998

0.952–1.046

0.934

Hypertension(N/Y)

1.884

0.816–4.347

0.138

HDL-C(mmol/L)

2.060

0.716–5.930

0.180

TCH(mmol/L)

1.152

0.813–1.632

0.426

Smoker(N/Y)

0.755

0.217–2.621

0.658

Table 3. Correlation between CTRP1 and number of diseased coronary vessels (multivariate regression
analysis). Comparison single-vessel with double-vessel and triple-vessel lesion.

Variable

OR

OR CI95%

P

CTRP1(ng/ml)

1.066*

1.004–1.132

0.037

Sex(M/F)

0.384

0.132–1.119

0.079

Age(year)

1.041

0.992–1.092

0.106

Hypertension(N/Y)

1.016

0.441–2.343

0.970

HDL-C(mmol/L)

1.180

0.477–2.919

0.720

TCH(mmol/L)

1.151

0.802–1.650

0.446

Smoker(N/Y)

0.362

0.107–1.226

0.102

Table 4. Correlation between CTRP1 and number of diseased coronary vessels (multivariate regression
analysis). Comparison single-vessel and double-vessel with triple-vessel lesion.

Variable

OR

OR CI95%

Sex

8.92**

1.91–41.76

Age

0.82***

0.74–0.89

P
0.005
<0.001

Diabetes

207.82**

5.53–7811.55

0.004

CTRP5

1.17*

0.73–0.99

0.038

AST

0.96*

0.93–0.99

0.029

Table 5. Correlation between CAD and CTRPs (multivariate regression analysis). *p < 0.05. **p < 0.01.
**p < 0.001.

that CTRP1 is associated with the severity of vessel-lesion of CAD (Tables 3 and 4). CTRP5 may serve as an independent predictor for CAD.
To further clarify the relationship between CTRPs and CAD, we performed a serial analysis. First, as illustrated in Table 5, we build a multivariate model among the significant variables noted by univariate analysis to
determine potential screening markers for CAD. Results showed that CAD is highly correlated with Sex, age,
diabetes and AST (p < 0.05). CTRP5 was an independent predictor for CAD (Table 5). Meanwhile, Sex, age, diabetes, smoking, TCH, TG, HDL-C, ALT, CTRP1 and CTRP15 were significantly positively associated with CAD
(Table 6). Logistic regression analysis as shown in Table 7 and 8 indicated that reduced CTRP15 was a high-risk
factor for a single-vessel lesion in CAD whereas increased CTRP1, occlusion and smoking were the high-risk
factors for triple-vessel lesions of CAD.
To assess whether CTRPs can serve as a marker for CAD, a receiver operating characteristic (ROC) curve
was constructed to evaluate the diagnostic value of CTRPs for CAD. As illustrated in Fig. 1, the AUC (area under
the curve) was 0.626 for CTRP7 (P < 0.01, Fig. 1A, n = 120) and 0.665 for CTRP15 (p < 0.001, Fig. 1B, n = 120),
confirming specificity and sensitivity of CTRP7 and CTRP15 as biomarkers for CAD. The ROC analysis results of
CTRP5 and CTRP1 showed the AUC was 0.529 and 0.554 respectively, failed to serve as biomarkers for CAD as a
whole. Notably, the AUC of CTRP1 was 0.613 (95% confidence interval 0.509–0.718, P = 0.044) for single-vessel
lesions (Fig. 2A), and AUC was 0.650 (p = 0.007) for triple-vessel (Fig. 2B). Furthermore, the AUC of CTRP1 for
multiple-vessel lesions was 0.613 (p = 0.044) (Fig. 2C), hence, CTRP1 value was the optimistic selected models for prognosticating vessel-lesions in CAD. Although the AUC of CTRP5 for triple-vessel lesions was 0.642
(p = 0.011), the signal-vessel lesion and multiple-vessel lesion failed to serve as a marker (Fig. 3). Taken together,
these results suggest that CTRP7 and CTRP15 may serve as biomarkers for CAD as whole while CTRP1 may
serve as a marker for severity of vessel-lesions.
To identify the etiology of altered CTRPs in CAD patients, we examined whether CTRPs is associated with
other risk factors. Multiple linear regression was used to determine the relationship of CTRPs with other risk
factors. As shown in Tables 9 and 10, the results revealed that CTRP5 and CTRP7 were not associated with
any other variables. However, serum CTRP1 was positively associated with age and vascular occlusion. When
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Univariate Analysis
Variable

ORCI95%

P

Sex(M/F)

6.846***

3.56–13.18

<0.001

Age(year)

1.15**

1.11–1.20

0.001

2.92–165.41

0.003

Diabetes(N/Y)

OR

21.99**

Smoker(N/Y)

3.69*

1.04–13.07

0.043

TCH(mmol/L)

0.69**

0.53–0.90

0.007

TG(mmol/L)

1.97**

1.27–3.06

0.002

HDL-C(mmol/L)

0.17**

0.06–0.47

0.001

LDL-C(mmol/L)

1.04

0.83–1.31

0.710

ALT(U/L)

1.03*

1.01–1.05

0.011

AST(U/L)

1.02

0.10–1.03

0.114

EF(%)

0.97

0.92–1.02

0.198

CTRP1(ng/ml)

1.06*

1.01–1.12

0.022

CTRP5(ng/ml)

1.05

0.10–1.11

0.058

CTRP7(ng/ml)

1.00

0.99–1.01

0.967

CTRP15(ng/ml)

0.99**

0.98–0.10

0.009

Table 6. Logistic regression analysis of related risk factors. for CAD. **p < 0.01.*p < 0.05. **p < 0.001.

Univariate Analysis
Variable

OR

ORCI95%

P

Sex(M/F)

1.307

0.547–3.119

0.547

Age(year)

0.970

0.931–1.010

0.143

Occlusion(N/Y)

0.524

0.160–1.710

0.284

Hypertension(N/Y)

0.815

0.377–1.761

0.603

Diabetes(N/Y)

0.871

0.355–2.138

0.763

Smoker(N/Y)

1.485

0.519–4.247

0.461

TC(mmol/L)

0.890

0.636–1.246

0.498

TG(mmol/L)

0.834

0.586–1.186

0.312

HDL-C(mmol/L)

0.822

0.331–2.044

0.674

LDL-C(mmol/L)

0.792

0.548–1.146

0.216

ALT(U/L)

0.992

0.976–1.007

0.287

AST(U/L)

0.987

0.967–1.008

0.219

EF(%)

1.013

0.968–1.061

0.572

CTRP1(ng/ml)

0.945

0.892–1.000

0.051

CTRP5(ng/ml)

1.039

0.997–1.083

0.067

CTRP7(ng/ml)

0.998

0.991–1.005

0.571

CTRP15(ng/ml)

1.011*

1.000–1.023

0.045

Table 7. Logistic regression analysis of related risk factors for single-vessel of CAD. *p < 0.05.

other variables remain the same, CTRP1 increases by 0.088 ng/ml for each additional year of age (Table 9).
Meanwhile, there was no evidence revealing the positive interrelationship among the CTRP family members in
CAD population.
In contrast, age, diabetes, and TCH had a significant association with CTRP15. Serum CTRP15 was inversely
correlated with age and diabetes, but TG was positively correlated with CTRP15. In order to further determine
the relationship between CTRPs and severity of vessel-lesions in coronary artery disease, we have studied the
correlation between the number of lesions in CAD and clinical indicators. The results showed that CTRP1 level is
positively correlated with AST in single-vessel disease (Table 11). CTRP15 and diabetes were negatively correlated
with the three-vessel disease (Table 12).

Discussion

We reported a discovery of new biomarkers for coronary artery disease. The current study demonstrated that
CTRP7 and CTRP15 may serve novel biomarkers of CAD, and CTRP1 may predict the vessel-lesion severity in
CAD. Moreover, CTRP5 may serve an independent predictor for CAD. In addition, compared with the control
group, concentrations of both CTRP5 and CTRP7 were significantly decreased in CAD patients while CTRP1
concentrations were elevated.
In recent years, there have been many studies investigating serum levels of CTRP1 and coronary artery disease. Studies have shown that CTRP1 is a marker of human atherosclerosis and promotes atherosclerosis in
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Univariate Analysis
Variable

OR

ORCI95%

P

Sex(M/F)

1.588

0.670–3.763

0.293

Age(year)

1.019

0.978–1.061

0.363

Occlusion(N/Y)

3.000*

1.079–8.341

0.035

Hypertension(N/Y)

1.747

0.812–3.760

0.154

Diabetes(N/Y)

1.588

0.670–3.763

0.293

Smoker(N/Y)

3.69*

1.04–13.07

0.043

TC(mmol/L)

1.162

0.837–1.613

0.370

TG(mmol/L)

1.278

0.945–1.727

0.112

HDL-C(mmol/L)

2.170

0.768–6.131

0.144

LDL-C(mmol/L)

1.346

0.974–1.859

0.071

ALT(U/L)

1.005

0.996–1.014

0.391

AST(U/L)

1.007

0.995–1.018

0.263

EF(%)

0.986

0.92–1.02

0.531

CTRP1(ng/ml)

1.052*

1.006–1.099

0.025

CTRP5(ng/ml)

0.971

0.925–1.020

0.243

CTRP7(ng/ml)

1.002

0.996–1.007

0.621

CTRP15(ng/ml)

0.994

0.982–1.006

0.334

Table 8. Logistic regression analysis of related risk factors for triple-vessel of CAD. *p < 0.05.

mice17–19. The serum of the three-vessel disease had a high concentration of CTRP1 than the single-vessel disease,
which was consistent with our findings. Our results indicated that compared with non-CAD people, the serum
level of CTRP1 was elevated and correlated with CAD. CTRP1 highly correlated with the stages of vessel-lesion.
Although CTRP1 was a significant factor for predicting vessel-lesion stages in CAD, it failed to be a diagnostic
biomarker to CAD. This is inconsistence with previous report by other group13. Small patients’ populations and
limited race (Chinese Han population) could be the reason to cause this discrepancy. However, it acts as a biomarker for the increase of the vessel-lesion level. The increased level of CTRP1 in circulation may be attributed
to disturbed flow and other risk factors-induced inflammatory cytokines20,21. To further explore the risk factor
for elevated CTRP1 and elaborate the relationship between clinical indicators and CTRP1, we applied multiple
linear regression assay. The results indicated that plasma CTRP1 levels were positively correlated with age and
vascular occlusion. Furthermore, CTRP1 was positively correlated with AST in single-vessel disease. Despite the
advantageous findings of our study regarding the role of CTRP1 in CAD related vessel lesion, we recognize some
limitations. We did not investigate other vascular disease relationship with CTRP1 and other possible pathogenic
molecules including other CTRP family members. It is highly desirable to conduct additional studies regarding
CTRP1 role in pathogenesis of CAD with larger samples of patients utilizing prospective designs.
CTRP5 is wildly expressed in various cells, with the highest expression level in adipose tissue22. It inhibits
adiponectin and resistin release in a dose-dependent manner16. Simultaneously, CTRP5 can promote transcytosis
and oxidative modification of low-density lipoprotein and accelerate atherosclerosis development23. Studies have
shown that CTRP5 can be used as a biomarker for potential new inflammatory chronic obstructive pulmonary
disease and in patients with coronary in-stent restenosis since serum CTRP5 levels are significantly elevated24.
However, there are few studies investigated the relationship between CTRP5 and coronary artery disease. In our
study, we divided the recruited patient’s population into two groups (elder and young) in the normal physical
examination group. Three stages of vessel-lesion in diagnosed as coronary artery disease group and the CTRP5
levels were compared among the groups. The results showed no differences within the non-CAD group in different age. However, CTRP5level was increased in CAD group when compared with non-CAD. Notably, the
concentration of serum CTRP5 shown an increasing tendency in a single-vessel lesion group than the three-vessel
lesion group. The small sample size and the controversial deleterious effect of CTRP5 in the vascular system may
contribute to the unparalleled phenomenon between CTRP5 and the level of vessel lesions16,23,25.
Although circulating CTRP7 level has been reported to be elevated in obese people, and CTRP7 knockout
mice exhibit elevated glucose metabolism, decreased adipose tissue inflammation, liver fibrosis, cellular oxidation, and endoplasmic reticulum stress in10, the CTRP7 circulating levels and coronary artery disease is largely
unknown. Studies have shown that circulating CTRP15 concentration and its gene expression are affected by
metabolism26. CTRP15 may potentially be used as a circulating biomarker for predicting cardiovascular disease (CVD) risk in obese and T2DM patients27. In our study, serum CTPR7 and CTRP15 levels in CAD were
reduced compared with the non-CAD group. CTRP7 and CTRP15 are novel identified diagnostic biomarker for
CAD, while CTRP1 and CTRP5 fail in this study. These results suggest that CTRP7 and CTRP15 presents more
sensitivity and stability as biomarkers than the other two. Meanwhile, the result showed that CTRP15 was negatively correlated with age and diabetes in coronary artery disease patients; and it is positively correlated with TG
levels. Further analysis revealed that the negative correlation between CTRP15 and diabetes is significant in the
three-vessel lesion of CAD.
We further carried out multiple regression analysis and found that CTRP5 can be an independent indicator
for CAD, but it failed to predict the severity of vessel-lesion, and CTRP5 might be a possible therapeutic target in
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A

ROC curves, for CAD diagnosis, by circulang
CTRP7 level.

Variable

AUC

SE

P-value

95%CI

CTRP7 (ng/ml)

0.626

0.041

0.004

0.546-0.706

C

B

ROC curves, for CAD diagnosis, by
circulang CTRP15 level.

Variable

CTRP15 (ng/ml) 0.665

D

ROC curves, for CAD diagnosis, by
circulang CTRP5 level.

AUC

SE

P-value

95%CI

0.040

<0.001

0.587-0.743

ROC curves, for CAD diagnosis, by
circulang CTRP1 level.

Variable

AUC

SE

P-value

95%CI

Variable

AUC

SE

P-value

95%CI

CTRP5(ng/ml)

0.529

0.042

0.512

0.447-0.610

CTRP1 (ng/ml)

0.554

0.041

0.211

0.473-0.635

Figure 1. ROC curves for CAD diagnosis by CTRPs level. (A) ROC curves for CAD diagnosis by CTRP7 level.
(B) ROC curve for CAD diagnosis by circulating CTRP15 level. (C) ROC curve for CAD diagnosis by CTRP5
level. (D) ROC curve for CAD diagnosis by CTRP1 level.

prevention or ameliorating CAD in future study. In addition, consistent with other studies28, gender, age, diabetes,
and AST are all risk factors for CAD.
Our research has some limitations. The first is relatively small sample size and is Chinese Han population
only. Secondly, our survey was a case-controlled study by which it cannot determine the incident rate of disease
in exposed and non-exposed groups. Thirdly, we utilized AUC >0.6 as cutoff for the resultant logistic-regression
based ROC analyses. However, CTRPs are not pre-existing risk model in CAD and our study was restricted to a
small study size. This factors AUC has value for evaluating CAD risks even with a cutoff value of 0.6. Fourthly,
mechanisms causing circulating CTRPs level alteration need to be further explored. Our preliminary experiments suggest that unbalanced miRNA pool produced by dysfunctional adipocytes may initiate pathological
long-distance communication between adipocytes and cardiomyocytes, causing CTRPs level alteration, abnormal
CTRP9 assembling and expression. Finally yet importantly, we needed additional in vivo animal studies to elucidate the physiology and mechanism of action of CTRP in the development of CAD.
In conclusion, we have demonstrated that circulating CTRP1 can predict the severity of vessel-lesions in coronary artery disease, and CTRP7 and CTRP15 can serve as new CAD diagnostic biomarker. In addition, our study
showed that CTRP15 is inversely associated with diabetes in three-vessel coronary artery disease. CTRP5 is the
independent risk for CAD. The new discovered CTRPs provide the future therapeutic target and pre-diagnostic
biomarker for coronary artery disease.
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A

Variable

ROC curves, for single-vessel-lesion
of CAD diagnosis

AUC

SE

P-value

95%CI

B

ROC curves, for triple-vessel-lesion
of CAD diagnosis

Variable

AUC

SE

CTRP1(ng/ml) 0.613 0.053 0.044 0.509-0.718 CTRP1(ng/ml) 0.650 0.052

C

P-value

95%CI

0.007

0.548-0.752

ROC curves, for mulple-vessel-lesion of
CAD diagnosis, by circulang CTRP1 level.

Variable

AUC

SE

P-value

95%CI

CTRP1˄ng/ml)

0.613

0.053

0.044

0.509-0.717

Figure 2. ROC curves for vessel-lesion of CAD diagnosis by CTRP1 level. (A) ROC curve for single-vessellesion of CAD diagnosis by CTRP1 level. (B) ROC curve for triple-vessel-lesion of CAD diagnosis by CTRP1
level. (C) ROC curve for multiple-vessel-lesion of CAD diagnosis by CTRP1 level.

Methods

Participants and eligibility.

The patients were enrolled in the first affiliated Hospital of Shanxi Medical
University from January 2017 to September 2018. A total of 190 subjects attended. The research included 40
healthy control subjects, 30 patients without stenosis after coronary angiography, and 120 patients with coronary
artery disease (40 patients with a single vessel, 40 patients with double-vessel and 40 patients with triple-vessel).
All research protocols were approved by the Ethics Committee of Shanxi Medical University and performed in
accordance with the latest version of the Declaration of Helsinki. Moreover, all patients and control subjects
were given written informed consent. The diagnostic criteria of CAD were a 50% or greater organic stenosis of
at least one main coronary artery as confirmed by coronary angiogram, two stenosis ≥50% was considered as a
double-vessel disease, and more than two stenoses was defined as a triple-vessel disease. Exclusion criteria for this
study were: old myocardial infarction, congestive heart failure, severe hepatic and renal dysfunction, malignancy,
a history of trauma or surgery within one-month, valvular heart disease, pregnancy, or any factor affecting body
weight such as hyperthyroidism, corticosteroids, or contraceptives, or acute and chronic infection.

Biochemical and hormonal analysis. The arterial blood extracted directly from the sheath of radial artery
before coronary angiography was separated into the Eppendorf tube at 4 °C for 20 minutes by 3000 rpm centrifugation, then frozen and stored at −80 °C until determined. Total cholesterol(TC), triglycerides(TG), high-density
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A

B

ROC curves, for triple-vessel of CAD diagnosis, by circulang CTRP5 level.

Variable

AUC

SE

P-value

95%CI

CTRP5 (ng/ml)

0.642

0.058

0.011

0.528-0.756

ROC curves, for mulple-vessel of CAD diagnosis, by circulang CTRP5 level.

Variable

AUC

SE

P-value

95%CI

CTRP5(ng/ml)

0.591

0.054

0.106

0.485-0.697

Figure 3. ROC curves for vessel-lesion of CAD diagnosis by CTRP5 level. (A) ROC curve for triple-vessellesion of CAD diagnosis by CTRP5 level. (B) ROC curve for multiple-vessel-lesion of CAD diagnosis by CTRP5
level.

Variable

SE

P

Sex(M/F)

0.984

1.248

0.431

Age(year)

0.088*

0.042

0.037

Occlusion(N/Y)

4.445*

1.889

0.020

Diabetes(N/Y)

0.733

1.698

0.666

TCH(mmol/L)

−0.531

0.546

0.332

HDL-C(mmol/L)

1.253

1.326

0.346

Smoker(N/Y

2.791

1.903

0.144

AST(U/L)

0.022

0.017

0.202

TG(mmol/L)

0.906

0.506

0.075

Hypertension(N/Y)

0.033

1.526

0.983

β

Table 9. Multiple linear regression analysis of CTRP1 and clinical indicators. *p < 0.05.
Variable

β

SE

P

5.832

0.470

Sex(M/F)

4.222

Age(year)

−0.606**

0.196

0.002

2.675

8.828

0.762

Occlusion(N/Y)
Diabetes(N/Y)

−19.379*

7.935

0.016

TCH(mmol/L)

6.162*

2.553

0.017

HDL-C(mmol/L)
Smoker(N/Y)

−5.271

6.197

0.396

4.577

8.893

0.607

AST(U/L)

−0.132

0.081

0.104

TG(mmol/L)

−0.990

2.365

0.676

Hypertension(N/Y)

11.924

7.134

0.096

Table 10. Multiple linear regression analysis of CTRP15 and clinical indicators. *p < 0.05.
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Variable

β

SE

P

Sex(M/F)

−0.705

2.685

0.795

Age(year)

0.119

0.138

0.395

Occlusion(N/Y)

0.406

3.626

0.912

Diabetes(N/Y)

2.589

2.413

0.292

TCH(mmol/L)

−0.049

1.276

0.969

HDL-C(mmol/L)

1.745

5.786

0.765

Smoker(N/Y

4.298

2.935

0.154

AST(U/L)

0.168*

0.079

0.044

TG(mmol/L)

0.777

1.056

0.468

Hypertension(N/Y)

1.593

2.256

0.486

Table 11. Multiple linear regression analysis of CTRP1 and clinical indicators in single-vessel. *p < 0.05.
Variable

SE

β

P

Sex(M/F)

12.408

13.942

0.381

Age(year)

−0.723

0.829

0.390

Occlusion(N/Y)

−3.458

13.430

0.799

Diabetes(N/Y)

−32.302*

15.032

0.040

TCH(mmol/L)
HDL-C(mmol/L)
Smoker(N/Y)
AST(U/L)
TG(mmol/L)
Hypertension(N/Y)

0.190

5.196

0.971

−2.816

7.637

0.715

2.251

17.093

0.896

−0.092

0.128

0.478

0.145

3.202

0.964

25.093

14.429

0.093

Table 12. Multiple linear regression analysis of CTRP15 and clinical indicators in triple-vessel.
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, homocysteine (HCY) were determined
by commercial kit via Hitachi 7600 biochemical automatic analyzer (Hitachi, Tokyo, Japan).

Echocardiographic examination.

The echocardiographic measurements were carried out while the
patients were in the left lateral decubitus with standard precordial positions by Philips Epiq 7C Cardiology
Ultrasound machine (Los Angeles, CA, USA). The left ventricle ejection fraction (LV EF) was assessed with
biplane method of disks (modified Simpson’s rule) according to the American Society of Echocardiography
(ASE). LVEF = [(LV end-diastolic volume)- (LV end-systolic volume)]/ (LV end-diastolic volume).

Measurement of plasma CTRP1, CTRP5, CTRP7 and CTRP15. Plasma CTRP1, CTRP5, CTRP7, and
CTRP15 levels were measured by commercial enzyme-linked immunosorbent assay (ELISA) kit (Cat, SK0008301 for CTRP1; Cat, SK00594-06 for CTRP5; Cat, SK00396-09 for CTRP7; SK00393-19 for CTRP15, Aviscera
Bioscience, Santa Clara, CA) per manufacturer’s instructions. Intra- and inter-assay coefficients of variation (CV)
for CTRP1, CTRP5, and CTRP15 were 6–8% and 8–12% respectively, and intra- and inter-assay coefficients of
variation for CTRP7 were 4–6% and 8–10%, respectively.
Statistical analysis.

Descriptive analysis was applied, and quantitative data were conducted by the
Shapiro-Wilk test for normality. Continuous variables are expressed as mean ± standard error (SE). Data (Sex,
Smoker, Diabetes) that did not conform to normality distribution were expressed as median ± interquartile (IQR).
We first examined differences between groups of the phenotypes of interest in the control, single-vessel-lesion,
double-vessel-lesion, and triple-vessel-lesion by the Mann-Whitney U test to compare of continuous variables
and the Chi-square test for statistical inference of categorical variables. To assess the effect of the subjects with
different lesions, we applied a Chi-square test on different groups.
Next, we used logistic regression to estimate the association between CAD and case-control status of all other
parameters as defined above. In addition to the use of multivariate regression for determining potential screening
markers for CAD, we adjusted our model for other risk factors by univariate regression analysis and evaluated the
collinearity diagnostics. The predicted probability of being diagnosed with CAD was used as a surrogate marker
to construct receiver operating characteristic (ROC curves). The area under the ROC curve (AUC) served as an
accuracy index evaluating the diagnostic performance of the noted marker. We used multiple linear regression to
describe the dependencies between CTRPs and multiple independent variables in CAD.
All statistical analyses were performed using SPSS 20.0 (Chicago, IL, USA). P-value less than 0.05 in a
two-tailed test were considered statistically significant.
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